Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 4, 2005, Pages 364-368

  Spicer, J ^a,b   Plunkett, T ^a   Somaiah, N ^a   Chan, S ^a   Kendall, A ^a   Bolunwu, N ^a   Pandha, H ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Capecitabine; Chemotherapy; PSA

Indexed keywords

CAPECITABINE; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; LYMPHOCYTOPENIA; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SOFT TISSUE METASTASIS; TREATMENT FAILURE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANDROGENS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 30544439826     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500821     Document Type: Article

References (29)

1. Tannock IF et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764.
2. Kantoff PW et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506-2513.
3. Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
4. Tannock IF et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
5. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115.
6. Borner MM et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349-358.
7. Kelly WK et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001; 19: 44-53.
8. Kuzel TM et al. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer 1993; 72: 1965-1968.
9. Huan SD, Aitken SE, Stewart DJ. 5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: A phase II study. Ann Oncol 1994; 5: 644-645.
10. Atkins JN et al. Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol 1996; 19: 23-25.
11. Breul J et al. 5-Fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone-resistant prostate cancer: A prospective randomized pilot trial. Eur Urol 1997; 32: 280-283.
12. Berlin JD et al. 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: An Eastern Cooperative Oncology Group phase II study (E1889). Am J Clin Oncol 1998; 21: 171-176.
13. Hansen R et al. Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer. Urology 1991; 37: 358-361.
14. Bex A, Otto T, Lummen G, Rubben H. Phase II study of repeated single 24-hour infusion of low-dose 5-fluorouracil for palliation in symptomatic hormone-refractory prostate cancer. Urol Int 2002; 69: 273-277.
15. Miwa M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281.
16. Sivridis E et al. Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: Correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis. Br J Cancer 2002; 86: 1465-1471.
17. Hoff PM et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-2292.
18. Van Cutsem E et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106.
19. Blum JL et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-493.
20. O'Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
21. El-Rayes BF, Black CA, Ensley JF. Hormone-refractory prostate cancer responding to capecitabine. Urology 2003; 61: 462.
22. Bubley GJ et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
23. Mackean M et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/ or metastatic cancer. J Clin Oncol 1998; 16: 2977-2985.
24. Therasse P et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
25. Gehan E. Determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13: 346.
26. Morant R et al. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br J Cancer 2004; 90: 1312-1317.
27. Wu JT. Assay for prostate specific antigen (PSA): Problems and possible solutions. J Clin Lab Anal 1994; 8: 51-62.
28. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998; 16: 1835-1843.
29. Wieder JA, Belldegrun AS. The utility of PSA doubling time to monitor prostate cancer recurrence. Mayo Clin Proc 2001; 76: 571-572.